Dr. Farshid Dayyani
Claim this profileUC Irvine Health/Chao Family Comprehensive Cancer Center
Expert in Gastroesophageal Junction Adenocarcinoma
Studies Cancer
25 reported clinical trials
54 drugs studied
About Farshid Dayyani
Education:
- Earned an MD from Ludwig Maximilian University of Munich, Germany (Class of 2002).
- Completed Residency in Internal Medicine at Beth Israel Deaconess Medical Center (2006-2008).
- Undertook a Fellowship in Hematology and Medical Oncology at the University of Texas Health Science Center at Houston/MD Anderson Cancer Center (2008-2011).
Experience:
- Serves as Associate Director for Translational Science at UC Irvine Health/Chao Family Comprehensive Cancer Center.
- Holds the position of Medical Director for the Stern Center for Cancer Clinical Trials & Research.
- Appointed Chief of the Division of Hematology/Oncology at UC Irvine School of Medicine.
- Actively involved in clinical trials as Principal Investigator.
Area of expertise
1Gastroesophageal Junction Adenocarcinoma
Global LeaderStage IV
Stage III
HER2 positive
2Cancer
Stage IV
Stage III
HER2 positive
Affiliated Hospitals
Clinical Trials Farshid Dayyani is currently running
Triapine + Targeted Radiation
for Neuroendocrine Cancer
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.
Recruiting1 award Phase 2
ctDNA-Guided Therapy
for Colorectal Cancer
This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.
Recruiting1 award Phase 1
More about Farshid Dayyani
Clinical Trial Related1 year of experience running clinical trials · Led 25 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Farshid Dayyani has experience with
- Nivolumab
- Irinotecan
- Cabozantinib
- TAS-102
- Docetaxel
- Paclitaxel
Breakdown of trials Farshid Dayyani has run
Gastroesophageal Junction Adenocarcinoma
Cancer
Skin Cancer
Stomach Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Farshid Dayyani specialize in?
Farshid Dayyani focuses on Gastroesophageal Junction Adenocarcinoma and Cancer. In particular, much of their work with Gastroesophageal Junction Adenocarcinoma has involved Stage IV patients, or patients who are Stage III.
Is Farshid Dayyani currently recruiting for clinical trials?
Yes, Farshid Dayyani is currently recruiting for 10 clinical trials in Orange California. If you're interested in participating, you should apply.
Are there any treatments that Farshid Dayyani has studied deeply?
Yes, Farshid Dayyani has studied treatments such as Nivolumab, Irinotecan, Cabozantinib.
What is the best way to schedule an appointment with Farshid Dayyani?
Apply for one of the trials that Farshid Dayyani is conducting.
What is the office address of Farshid Dayyani?
The office of Farshid Dayyani is located at: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California 92868 United States. This is the address for their practice at the UC Irvine Health/Chao Family Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.